Fluorescent End-Labeling and Encapsulation of Long RNAs for Single-Molecule FRET-TIRF Microscopy

Executive Industry Relevance

Direct dual-end fluorescent labeling and vesicle encapsulation of long RNAs enable high-resolution, real-time monitoring of RNA conformational dynamics at the single-molecule level. This capability is critical for de-risking mechanistic hypotheses and validating functional RNA targets in early discovery. The approach supports predictive confidence in RNA-targeted drug discovery pipelines by providing quantitative, physiologically relevant readouts.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct observation of RNA folding and conformational changes under controlled conditions.
• Supports mechanistic de-risking by revealing structure-function relationships in catalytically active and regulatory RNAs.
• Facilitates functional target validation for complex RNA species, including group II introns and riboswitches.

Screening & Assay Development

• Provides a standardized workflow for covalent end-labeling of diverse RNAs using commercially available reagents.
• Delivers reproducible, quantitative FRET outputs suitable for downstream screening and comparative studies.
• Enables preparation of single-RNA vesicle systems for robust, high-content single-molecule assays.

Translational & Preclinical Research

• Aligns with translational biomarker strategies by supporting studies under near-physiological and cellular conditions.
• Maintains continuity from discovery-stage mechanistic interrogation to preclinical validation of RNA function.
• Reduces biological risk by providing dynamic, real-time evidence of RNA behavior relevant to disease models.

Pipeline & Workflow Integration

This method integrates into the discovery-to-preclinical continuum by enabling hypothesis-driven interrogation of RNA targets, quantitative assay development, and translationally relevant mechanistic studies.

• Discovery Biology: Supports null hypothesis testing and pathway clarification for RNA-mediated mechanisms.
• Screening: Delivers reproducible, quantitative FRET measurements for comparative analysis of RNA states.
• Analytics: Provides single-molecule resolution and dynamic readouts for robust statistical analysis.
• Translational Research: Facilitates studies under conditions mimicking physiological environments.
• Enterprise Reuse: Offers a broadly adaptable labeling and encapsulation protocol for diverse RNA targets.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in RNA target validation.
• Operational Value: Standardizes RNA labeling and encapsulation for scalable, reproducible workflows.
• Strategic Value: Improves go/no-go decision-making and capital allocation by providing quantitative, real-time data.
• Portfolio Impact: Enables risk-adjusted prioritization of RNA-targeted programs based on dynamic functional evidence.

Implementation Considerations

• Requires expertise in RNA chemistry, fluorescence labeling, and single-molecule microscopy.
• Demands access to TIRF microscopy and analytical infrastructure for FRET data acquisition and analysis.
• Necessitates cross-team standardization of labeling, encapsulation, and imaging protocols.
• Adaptable to a range of RNA sizes and sequences, but optimization may be needed for highly structured RNAs.
• Dependent on the availability of high-purity reagents and rigorous quality control at each workflow stage.

Biopharma FAQs